Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Merck's $5.85/share offer represented a ~312% premium over Immune Design's depressed close, reflecting platform-acquisition logic following the CMB305 Phase…
SVB Leerink's Jonathan Chang said the deal would 'bolster Merck's vaccine capabilities' and viewed competing bidders as unlikely, citing the existing G100 +…
Nine-month negotiation backstory: 'Merck proposed acquiring the company for $200 million in cash, with two potential further payments of $85 million,' before…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Merck agreed to acquire Immune Design for $5.85/share, or approximately $300 million, to add the GLAAS and ZVex platforms used to develop cancer vaccines and immunotherapies. Closed Q2 2019.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Immune Design Corp. (this deal) | 2019 | $300M | — |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2019 deals · Merck & Co. Inc. deals · Infectious Disease deals